Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [3H]dopamine and [3H]norepinephrine release

Biochemical Pharmacology

Volumn 86, Issue 5, 2013, Pages 656-665

  Narayanaswami, Vidya ^a   Somkuwar, Sucharita S ^a   Horton, David B ^a   Cassis, Lisa A ^b   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Angiotensin II receptors; Dopamine; Nicotinic acetylcholine receptors; Norepinephrine; Reward; Smoking

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; DOPAMINE; LOSARTAN; MECAMYLAMINE; NICOTINE; NORADRENALIN;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; HYPOTHALAMUS; IC 50; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT;

EID: 84884901989     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.025     Document Type: Article

References (61)

1. Center for Disease Control (CDC) Report, 2010 http://www.cdc.gov/tobacco/ data-statistics/sgr/2010/index.htm.
2. Balfour DJ. The neurobiology of tobacco dependence: a commentary. Respiration 2002;69:7-11. (Pubitemid 34158380)
3. Corrigall WA, Franklin KBJ, Coen KM, Clark PBS. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992;107:285-9.
4. Brunzell DH, Picciotto MR. Molecular mechanisms underlying the motivation-al effects of nicotine. Nebr Symp Motiv 2009;55:17-30.
5. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharma-cology 2004;47(1):227-41. (Pubitemid 39298267)
6. Wise RA. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci 2009;32:517-24.
7. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35:217-38.
8. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 2004;54(2):65-71. (Pubitemid 39315091)
9. McBride PE. The health consequences of smoking. Cardiovascular diseases. Med Clin North Am 1992;76(2):333-53.
10. Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 2010;122(15):1520-44.
11. Sawchenko PE, Swanson LW. The organization of noradrenergic pathways from the brainstem to the para-ventricular and supraoptic nuclei in the rat. Brain Res Rev 1982;4:275-325. (Pubitemid 13224880)
12. Harland D, Gardiner SM, Bennett T. Paraventricular nucleus injections of noradrenaline: cardiovascular effects in conscious Long-Evans and Brattleboro rats. Brain Res 1989;496:14-24. (Pubitemid 19212341)
13. Sharp BM, Matta SG. Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: dose-dependency and desensitization. Endocrinology 1993;133(1):11-9. (Pubitemid 23206368)
14. Millar NS, Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009;56(1):237-46.
15. Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 2012;287(48):40207-15.
16. Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z, et al. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv 2009;55:31-63.
17. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the b2 subunit are involved in the reinfor-cing properties of nicotine. Nature 1998;39:173-7. (Pubitemid 28092475)
18. Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, et al. Distribution and pharmacology of alpha 6-containing nicotinic receptors analyzed with mutant mice. J Neurosci 2002;22:1208-17. (Pubitemid 34163722)
19. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004;65(6):1526-35. (Pubitemid 38668310)
20. Salminen O, Drapeau JA, McIntosh JM, Collins AC, Marks MJ, Grady SR. Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetyl-choline receptors isolated by breeding of null mutant mice. Mol Pharmacol 2007;71(6):1563-71. (Pubitemid 47010909)
21. Brunzell DH, Boschen KE, Hendrick ES, Beardsley PM, McIntosh JM. Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nico-tine. Neuropsychopharmacology 2010;35(3):665-73.
22. Clarke PB, Reuben M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor sub-types from striatal [3H]-dopamine release. Br J Pharmacol 1996;117:595- 606.
23. Luo S, Kulak JM, Cartier GE, Jacobsen RB, Yoshikami D, Olivera BM, et al. a- Conotoxin AuIB selectively blocks a3b4 nicotinic acetylcholine receptors and nicotine-stimulated norepinephrine release. J Neurosci 1998;18:8571-9. (Pubitemid 28491724)
24. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000;2(2):139-47.
25. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004;287:R943-9. (Pubitemid 39280483)
26. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24(3):261-71. (Pubitemid 36733542)
27. Lippoldt A, Paul M, Fuxe K, Ganten D. The brain renin-angiotensin system: molecular mechanisms of cell to cell interactions. Clin Exp Hypertens 1995;17(1-2):251-66.
28. Lynch KR, Simnad VI, Ben-Ari ET, Garrison JC. Localization of preangiotensino-gen messenger RNA sequences in the rat brain. Hypertension 1986;8(6): 540-3. (Pubitemid 16037830)
29. Phillips MI, Stenstrom B. Angiotensin II in rat brain comigrates with authentic angiotensin II in blood pressure liquid chromatography. Circ Res 1985;56:212-9. (Pubitemid 15131383)
30. Allen AM, MacGregor DP, Chai SY, Donnan GA, Kaczmarczyk S, Richardson K, et al. Angiotensin II receptor binding associated with nigrostriatal dopami-nergic neurons in human basal ganglia. Ann Neurol 1992;32:339-44.
31. Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept 1998;78(1-3):1-11. (Pubitemid 28561511)
32. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT (1)-receptor blockers. J Hum Hypertens 2002;16(3):S64-70. (Pubitemid 35021380)
33. Stadler T, Veltmar A, Qadri F, Unger T. Angiotensin II evoked noradrenaline release from the paraventricular nucleus in conscious rats. Brain Res 1992;569(1):117-22.
34. Siegl PK, Kivlighn SD, Broten TP. Pharmacology of losartan: an angiotensin II receptor antagonist, in animal models of hypertension. J Hypertens Suppl 1995;13(1):S15-21.
35. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens 1999;17(12 Pt 2):1775-86. (Pubitemid 30345311)
36. Ge J, Barnes NM. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 1996;297:299-306.
37. Brown DC, Steward LJ, Ge J, Barnes NM. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 1996;118(2):414-20. (Pubitemid 26149291)
38. Dwoskin LP, Jewell AL, Cassis LA. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn Schmiedebergs' Arch Pharmacol 1992;345(2):153-9.
39. Teng L, Crooks PA, Dwoskin LP. Lobeline displaces [3H] dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: com-parison with d-amphetamine. J Neurochem 1998;71(1):258-65. (Pubitemid 28292557)
40. Miller DK, Crooks PA, Dwoskin LP. Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology 2000;39(13):2654-62.
41. Miller DK, Sumithran SP, Dwoskin LP. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharma-col Exp Ther 2002;302(3):1113-22. (Pubitemid 34920233)
42. Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, et al. Repeated nicotine administration robustly increases bPiDDB inhibi- tory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol 2010;80(3): 402-9.
43. Blankley CJ, Hodges JC, Klutchko SR, Himmelsbach RJ, Chucholowski A, Con-nolly CJ, et al. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem 1991;34(11):3248-60.
44. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antag-onism displayed by DuP 753: an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252(2):719-25. (Pubitemid 20101889)
45. Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, et al. N,N0-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J Pharma-col Exp Ther 2008;326(2):563-76.
46. Cassis LA, Dwoskin LP. Presynaptic modulation of neurotransmitter release by endogenous angiotensin II in brown adipose tissue. J Neural Transm Suppl 1991;34:129-37.
47. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22(23):3099-108.
48. Flammia D, Dukat M, Damaj MI, Martin B, Glennon RA. Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J Med Chem 1999;42(18):3726-31. (Pubitemid 29445106)
49. Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor targeted therapeutics: advantages and limitations. Biochem Pharmacol 2011;82:915-30.
50. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, et al. Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283-94. (Pubitemid 28099739)
51. Yoshimura RF, Hogenkamp DJ, Li WY, Tran MB, Belluzzi JD, Whittemore ER, et al. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J Pharmacol Exp Ther 2007;323:907-15. (Pubitemid 350146068)
52. Zahniser NR, Dubocovich ML. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum. J Pharmacol Exp Ther 1983;227(3):592-9. (Pubitemid 14215039)
53. Dwoskin LP, Zahniser NR. Robust modulation of [3H]dopamine release from rat striatal slices by D-2 dopamine receptors. J Pharmacol Exp Ther 1986;239(2):442-53. (Pubitemid 17183169)
54. Saylor DL, Perez RA, Absher DR, Baisden RH, Woodruff ML, Joyner WL, et al. Angiotensin II binding sites in the hamster brain: localization and subtype distribution. Brain Res 1992;595:98-106.
55. MacGregor DP, Murone C, Song K, Allen AM, Paxinos G, Mendelsohn FA. Angiotensin II receptor subtypes in the human central nervous system. Brain Res 1995;675:231-40.
56. Jöhren O, Imboden H, Häuser W, Maye I, Sanvitto GL, Saavedra JM. Localization of angiotensin-converting enzyme: angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 1997;757(2):218-27. (Pubitemid 27244600)
57. Jain P, Armando I, Juorio AV, Barden N, Benicky J, Saavedra JM. Decreased hypothalamic and adrenal angiotensin II receptor expression and adrenome-dullary catecholamines in transgenic mice with impaired glucocorticoid re-ceptor function. Neuroendocrinology 2004;80(3):171-80.
58. Ernsberger P, Zhou J, Damon TH, Douglas JG. Angiotensin II receptor subtypes in cultured rat renal mesangial cells. Am J Physiol 1992;263(3 Pt 2):F411-6.
59. Macari D, Bottari S, Whitebread S, De Gasparo M, Levens N. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat. Eur J Pharmacol 1993;249(1):85-93. (Pubitemid 23326913)
60. Karamyan VT, Speth RC. Identification of a novel non-AT1, non-AT2 angioten-sin binding site in the rat brain. Brain Res 2007;1143:83-91. (Pubitemid 46440821)
61. Karamyan VT, Speth RC. Distribution of the non-AT1, non-AT2 angiotensin-binding site in the rat brain: preliminary characterization. Neuroendocrinology 2008;88(4):256-65.